Topics

NDA, sNDA for C. diff drug fidaxomicin accepted for review by FDA

05:43 EDT 3 Oct 2019 | SmartBrief

Merck's new drug application for its oral suspension form of fidaxomicin, indicated for the treatment of Clostridium difficil -More

Original Article: NDA, sNDA for C. diff drug fidaxomicin accepted for review by FDA

NEXT ARTICLE

More From BioPortfolio on "NDA, sNDA for C. diff drug fidaxomicin accepted for review by FDA"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...